《中国康复理论与实践》

《中国康复理论与实践》 ›› 2005, Vol. 11 ›› Issue (05): 384-385.

• 临床研究 • 上一篇    下一篇

血清抗髓鞘碱性蛋白抗体对多发性硬化的诊断价值

高枫; 李群彦; 郝洪军; 袁锦楣   

  1. 北京大学第一医院神经内科 北京市 100034
  • 收稿日期:2005-01-13 出版日期:2005-05-25 发布日期:2005-05-25

Value of anti-myelin basic protein antibody in patients with multiple sclerosis

GAO Feng, LI Qun-yan, HAO Hong-jun, et al   

  1. Department of Neurology, Peking University First Hospital,100034 Beijing, China
  • Received:2005-01-13 Published:2005-05-25 Online:2005-05-25

PDF (PC)

摘要： 目的探讨多发性硬化(MS)患者抗髓鞘碱性蛋白(MBP)抗体的临床意义。方法采用ELISA方法测定56例多发性硬化患者急性期血清抗髓鞘碱性蛋白抗体,与30例其他神经疾病(OND)患者及36 例正常人(NC)作对照。结果MS患者血清抗MBP抗体阳性率为78.6%,OND组抗MBP抗体阳性率为50%,与NC组比较均有显著性差异;MS患者与OND组患者抗MBP抗体阳性率比较亦有显著性差异。结论检测血清中抗MBP抗体,可为临床诊断和治疗多发性硬化提供指导。

关键词: 多发性硬化, 髓鞘碱性蛋白, 抗体, 诊断

Abstract: ObjectiveTo analyze the clinical value of anti-myelin basic protein (MBP) antibody in multiple sclerosis (MS).MethodsDetect the anti-MBP antibody in serum of 56 patients with MS, 30 patients with other neurological diseases (OND)and 36 normal control(NC).ResultsThe positive rate were 78.6% of MS, 50% of OND. There was significant difference amonge MS, OND and NC.ConclusionAnti-MBP antibody detection maybe provided evidence for the diagnosis and therapy of MS.

Key words: multiple sclerosis, myelin basic protein, antibody, diagnosis